Roquefort Therapeutics PLC - London-based biotech company focused on developing medicines for hard-to-treat cancers - Share suspension lifted, following the publication of its results Monday.

On Monday, Roquefort Therapeutics said it made a pretax loss of £1.6 million in 2022, widened from £917,433 the previous year. It also reported no revenue for last year, down from £719 in 2021. The company did not declare a dividend for 2022, unchanged from the prior year.

Current stock price: 6.92 pence, up 1.6% on Wednesday in London

12-month change: down 99%

Copyright 2023 Alliance News Ltd. All Rights Reserved.